Diagnosis of multiple sclerosis: progress and challenges WJ Brownlee, TA Hardy, F Fazekas, DH Miller The Lancet 389 (10076), 1336-1346, 2017 | 942 | 2017 |
Deep gray matter volume loss drives disability worsening in multiple sclerosis A Eshaghi, F Prados, WJ Brownlee, DR Altmann, C Tur, MJ Cardoso, ... Annals of neurology 83 (2), 210-222, 2018 | 445 | 2018 |
Progression of regional grey matter atrophy in multiple sclerosis A Eshaghi, RV Marinescu, AL Young, NC Firth, F Prados, ... Brain 141 (6), 1665-1677, 2018 | 384 | 2018 |
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic W Brownlee, D Bourdette, S Broadley, J Killestein, O Ciccarelli Neurology 94 (22), 949-952, 2020 | 216 | 2020 |
Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis WJ Brownlee, DR Altmann, F Prados, KA Miszkiel, A Eshaghi, ... Brain 142 (8), 2276-2287, 2019 | 187 | 2019 |
Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study M Filippi, P Preziosa, A Meani, O Ciccarelli, S Mesaros, A Rovira, ... The Lancet Neurology 17 (2), 133-142, 2018 | 153 | 2018 |
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome WJ Brownlee, DR Altmann, P Alves Da Mota, JK Swanton, KA Miszkiel, ... Multiple Sclerosis Journal 23 (5), 665-674, 2017 | 150 | 2017 |
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders O Ciccarelli, JA Cohen, SC Reingold, BG Weinshenker, MP Amato, ... The Lancet Neurology 18 (2), 185-197, 2019 | 149 | 2019 |
Longitudinal assessment of multiple sclerosis with the brain‐age paradigm JH Cole, J Raffel, T Friede, A Eshaghi, WJ Brownlee, D Chard, ... Annals of neurology 88 (1), 93-105, 2020 | 133 | 2020 |
Clinically isolated syndromes and the relationship to multiple sclerosis WJ Brownlee, DH Miller Journal of clinical neuroscience 21 (12), 2065-2071, 2014 | 132 | 2014 |
Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study T Schneider, W Brownlee, H Zhang, O Ciccarelli, DH Miller, ... Functional neurology 32 (2), 97, 2017 | 124 | 2017 |
Disease-modifying therapies for multiple sclerosis F De Angelis, NA John, WJ Brownlee bmj 363, 2018 | 123 | 2018 |
Incidence and prevalence of NMOSD in Australia and New Zealand W Bukhari, KM Prain, P Waters, M Woodhall, MOG Cullen, L Clarke, ... Journal of Neurology, Neurosurgery & Psychiatry 88 (8), 632-638, 2017 | 123 | 2017 |
Very long-term outcome after stroke in Auckland, New Zealand CS Anderson, KN Carter, WJ Brownlee, ML Hackett, JB Broad, R Bonita Stroke 35 (8), 1920-1924, 2004 | 107 | 2004 |
Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria WJ Brownlee, JK Swanton, DR Altmann, O Ciccarelli, DH Miller Journal of Neurology, Neurosurgery & Psychiatry 86 (5), 584-585, 2015 | 92 | 2015 |
An abnormal periventricular magnetization transfer ratio gradient occurs early in multiple sclerosis JWL Brown, M Pardini, WJ Brownlee, K Fernando, RS Samson, ... Brain 140 (2), 387-398, 2017 | 84 | 2017 |
Aggressive multiple sclerosis (1): Towards a definition of the phenotype E Iacobaeus, G Arrambide, MP Amato, T Derfuss, S Vukusic, B Hemmer, ... Multiple Sclerosis Journal 26 (9), 1031-1044, 2020 | 81 | 2020 |
Neurology in the time of COVID-19 H Manji, AS Carr, WJ Brownlee, MP Lunn Journal of Neurology, Neurosurgery & Psychiatry 91 (6), 568-570, 2020 | 81 | 2020 |
Differential diagnosis of suspected multiple sclerosis: an updated consensus approach AJ Solomon, G Arrambide, WJ Brownlee, EP Flanagan, MP Amato, ... The Lancet Neurology 22 (8), 750-768, 2023 | 76 | 2023 |
Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging R Cortese, F Prados Carrasco, C Tur, A Bianchi, W Brownlee, ... Neurology 100 (3), e308-e323, 2023 | 75 | 2023 |